Skip to main content
. 2020 Jul 2;8(5):nwaa155. doi: 10.1093/nsr/nwaa155

Figure 4.

Figure 4.

The biosafety of the Nano-SA-TCPP. (a) Cell viability of Hela cells with different concentrations of Nano-SA-TCPP. (b) The statistical body weight analysis of the experimental mice. (c) The Nano-SA-TCPP distribution and metabolization in the whole body observed by the fluorescence image of Nano-SA-TCPP. (d) Histology analysis of the major organs and tumors after treatment.